Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.